Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 813.89K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 10, $Monte Rosa Therapeutics(GLUE.US)$ Officer Jones Jullian G intends to sell 103.55K shares of its common stock on Apr 10, with a total market value of approximately $813
moomoo NewsApr 10 16:30 ET
Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler
TipRanksApr 9 07:06 ET
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Yahoo FinanceApr 4 09:55 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersStoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's market cap stands at $498.5 million. The company's, Q4 earnings came out
BenzingaMar 26 13:31 ET
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Simply Wall StMar 22 11:49 ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanksMar 19 08:11 ET
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results
Yahoo FinanceMar 16 05:31 ET
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
Yahoo FinanceMar 15 07:09 ET
Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)
TipRanksMar 15 05:17 ET
Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics
TipRanksMar 14 16:45 ET
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline
Monte Rosa Therapeutics (GLUE) reported Q4 net loss Thursday of $0.58 per diluted share, narrowing from the loss of $0.63 a year earlier. Analysts polled by Capital IQ expected a loss of $0.39. Cash a
MT NewswiresMar 14 14:11 ET
Monte Rosa Therapeutics Unveils Corporate Strategy Presentation
TipRanksMar 14 07:22 ET
Express News | Monte Rosa Therapeutics Q4 EPS $(0.58) Misses $(0.33) Estimate; Cash Balance Of $237M Is Expected To Provide Cash Runway Into First Half Of 2026
Moomoo 24/7Mar 14 07:12 ET
Press Release: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumo
Dow JonesMar 14 07:00 ET
Monte Rosa Therapeutics 4Q Loss/Shr 58c >GLUE
Monte Rosa Therapeutics 4Q Loss/Shr 58c >GLUE
Dow JonesMar 14 07:00 ET
Monte Rosa Therapeutics Cash Position Expected to Fund Ops Into 1H 2026 >GLUE
Monte Rosa Therapeutics Cash Position Expected to Fund Ops Into 1H 2026 >GLUE
Dow JonesMar 14 07:00 ET
Monte Rosa Therapeutics (GLUE) Receives a Buy From Piper Sandler
TipRanksMar 12 06:36 ET
Express News | Monte Rosa Therapeutics Announced MRT-8102 Is Expected To Be Developed For Inflammatory Diseases Driven By Interleukin-1β And The NLRP3 Inflammasome. This Is The First Development Candidate To Be Declared From The Company's NEK7 Development Program
Moomoo 24/7Mar 11 07:14 ET
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable across a range
GlobeNewswireMar 11 07:00 ET
Express News | CORRECTION: Wedbush Initiated Coverage on Monte Rosa Therapeutics on Thursday, Feb. 15
Moomoo 24/7Feb 16 12:01 ET
No Data
No Data